Protara announces results from Phase 2 STARBORN-1 trial of TARA-002

Protara Therapeutics (TARA) announced positive interim results from its ongoing Phase 2 open-label STARBORN-1 trial assessing intracystic injection of TARA-002, the Company’s investigational cell-based therapy, in pediatric patients with macrocystic and mixed cystic lymphatic malformations, LMs. STARBORN-1 Interim Results: 80% of patients that completed treatment achieved clinical success; 100% of patients who completed the eight-week response assessment achieved clinical success; 83% of macrocystic patients achieved a complete response and one patient achieved a substantial response; The only mixed cystic patient treated achieved a complete response; Two LMs patients reached the 32-week post-treatment assessment and remain disease-free; One patient deemed a complete response was subsequently diagnosed with a ranula; Two patients withdrew before the eight-week post-treatment assessment.